Spotlight On... Philips, Elekta start to install MRI-guided linear accelerator for next-gen cancer imaging, treatment; Nevro wins FDA approval for new Senza leads; St. Jude launches MultiPoint Pacing to tailor options; and more...

Partners Royal Philips ($PHG) and Elekta ($EKTA) have started installing a high-field, MRI-guided linear accelerator system at The Netherlands Cancer Institute in Amsterdam. The Institute is part of a consortium founded in 2012 by Elekta and Philips that's slated to make these sorts of systems, known as MR-linac, the standard of care for cancers that are not well controlled. The system uses a high-field MRI scanner to observe patient anatomy in real time, then it targets tumor tissue while minimizing exposure to the radiation beams for surrounding, normal tissue. "The clinical effectiveness of radiation treatment depends highly on the quality and accuracy of radiotherapy guidance and delivery," said Rob Cascella, CEO Imaging Businesses at Philips, in a statement. "In securing that quality and accuracy, MR imaging is emerging as a promising oncology tool for disease localization and quantification, therapy planning, treatment guidance, and therapy assessment. Through the collaboration with Elekta and the consortium partners such as The NKI, I am convinced that we have the prerequisites to make MR-guided radiotherapy a meaningful success for both patients and care providers." More

@FierceMedDev: Chinese TAVR player buys German third-gen peer, aims for global market after $37M from Goldman Sachs. More | Follow @FierceMedDev

@EmilyWFierce: Theranos CEO opens up about lab transgressions, 'devastated' by the fallout. Story | Follow @EmilyWFierce

> Varian Medical Systems ($VAR) disclosed a Phase III trial comparing outcomes for radiosurgery versus surgical resection to treat early-stage, high-risk, operable non-small cell lung cancer (NSCLC). More

> St. Jude Medical ($STJ) has launched MultiPoint Pacing tech, which is intended to let physicians tailor treatment to heart failure patients who don't respond to other pacing options. More

> Nevro ($NVRO) has gained FDA approval for new surgical leads for its Senza Spinal Cord Stimulation (SCS) System to treat chronic pain. More

Suggested Articles

The two companies also plan to identify new potential targets and therapeutic candidates for inflammatory bowel disease, or IBD.

This would allow centralized, lab-based diagnostic hardware to process blood samples at scale, screening patients for previous infections.

GlaxoSmithKline and AstraZeneca are considering forming a joint lab to help the U.K. expand its supplies for COVID-19 testing, according to Bloomberg.